Sprint Bioscience wins Vinnova grant of about SEK 940,000 for MAX IV fragment screening project

PUBT · 1d ago
Sprint Bioscience wins Vinnova grant of about SEK 940,000 for MAX IV fragment screening project
  • Sprint Bioscience, MAX IV won about SEK 940,000 from Sweden’s Vinnova for fragment-screening research to support drug discovery.
  • Sprint may receive up to about SEK 704,000; project runs from November 2026 to October 2028.
  • Work will compare cryogenic versus room-temperature fragment screening to assess temperature effects on fragment binding to target proteins.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sprint Bioscience AB published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.